Diffuse large B-cell triple-expressor lymphoma with atypical presentation as a Pancoast tumor
DOI:
https://doi.org/10.32818/reccmi.a11n1a12Keywords:
Pancoast tumor, diffuse large B-cell non- Hodgkin lymphoma (tripleexpressing)Abstract
Triple-expressing B-cell lymphoma is a poor-prognosis subtype of diffuse large B-cell lymphoma (DLBCL). We present
the case of a patient with multiple sclerosis who developed a Pancoast tumor of lymphoid etiology. The case is notable
for the diagnostic challenge posed by the discrepancy between an initial benign suspicion and an aggressive clinical
progression, characterized by the rapid onset of axillary deep vein thrombosis, hyperacute brachial plexopathy,
and Horner's syndrome.
Downloads
Metrics
References
Correia MS, Clark RF. Recurrent diffuse large B-cell lymphoma presenting with Pancoast syndrome: a rare cause of radicular neck pain in the emergency department. J Emerg Med. 2018; 55(3): 399–401. doi: http://dx.doi.org/10.1016/j.jemermed.2018.06.015 (último acceso abr. 2026). DOI: https://doi.org/10.1016/j.jemermed.2018.06.015
Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121(12): 2253–2263. doi: http://dx.doi.org/10.1182/blood-2012-06-435842 (último acceso abr. 2026). DOI: https://doi.org/10.1182/blood-2012-06-435842
Huang W, Medeiros LJ, Lin P, Wang W, Tang G, Khoury J, et al. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol. 2018; 31(9): 1470–1480. doi: http://dx.doi.org/10.1038/s41379-018-0067-x (último acceso abr. 2026). DOI: https://doi.org/10.1038/s41379-018-0067-x
Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: clinicopathologic features of 11 cases. Am J Surg Pathol. 2015; 39(8): 1132–1139. doi: http://dx.doi.org/10.1097/PAS.0000000000000434 (último acceso abr. 2026). DOI: https://doi.org/10.1097/PAS.0000000000000434
Laude M-C, Lebras L, Sesques P, Ghesquieres H, Favre S, Bouabdallah K, et al. First-line treatment of double-hit and triple-hit lymphomas: survival and tolerance data from a retrospective multicenter French study. Am J Hematol. 2021; 96(3): 302–311. doi: http://dx.doi.org/10.1002/ajh.26068 (último acceso abr. 2026). DOI: https://doi.org/10.1002/ajh.26068
Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017; 31(2): 37–42. doi: http://dx.doi.org/10.1016/j.blre.2016.09.004 (último acceso abr. 2026). DOI: https://doi.org/10.1016/j.blre.2016.09.004
Zhou Y, Wu Y, Zhao X, Xu L, Sun M, Meng Z. The real-world safety of ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system. Frontiers in Immunology. 2025; 16:1515730. doi: https://doi.org/10.3389/fimmu.2025.1515730 (último acceso abr. 2026). DOI: https://doi.org/10.3389/fimmu.2025.1515730
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 María Camila Luna, María Bielsa, Juan Vázquez, Margarita Elices Apellaniz, Olga Madridano
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
